This seven-year long case finally reached its conclusion in June 2020. In what surprised many pharma lawyers, the court upheld Kymab’s appeal, and revoked Regeneron’s patents. In fact, all but one judge backed the final verdict.

In October, the UK High Court rejected an appeal on AI inventorship in the debate around AI system Dabus. The judgment states an artificial intelligence system cannot be an inventor, upholding a decision by the UKIPO. Now the UKIPO, European Patent Office and United States Patent and Trademark Office have aligned views. But the UK Court of Appeal has granted permission to appeal on the basis of how important the principle at stake is.

In May, the Enlarged Board of Appeal at the EPO ruled that plants and animals obtained from ‘essentially biological processes’ are not patentable, in the long-fought battle over case G 3/19. The decision upheld Article 53(b) EPC: “European patents shall not be granted in respect of plant or animal varieties or essentially biological processes for the production of plants or animals; this provision shall not apply to microbiological processes or the products thereof.”

This bitterly-fought connected car battle between Nokia and Daimler has seen almost all procedural tricks that one could imagine in patent disputes. This includes anti-anti-suit-injunctions across the Atlantic, involvement of the EU Commission and the German Federal Cartel Office, and a full injunction win for Nokia weakened by a seven billion euro security deposit. Daimler and its suppliers challenged this, with a request to stay the enforcement of the injunction.

This seven-year long case finally reached its conclusion in June 2020. In what surprised many pharma lawyers, the court upheld Kymab’s appeal, and revoked Regeneron’s patents. In fact, all but one judge backed the final verdict.

In October, the UK High Court rejected an appeal on AI inventorship in the debate around AI system Dabus. The judgment states an artificial intelligence system cannot be an inventor, upholding a decision by the UKIPO. Now the UKIPO, European Patent Office and United States Patent and Trademark Office have aligned views. But the UK Court of Appeal has granted permission to appeal on the basis of how important the principle at stake is.

In May, the Enlarged Board of Appeal at the EPO ruled that plants and animals obtained from ‘essentially biological processes’ are not patentable, in the long-fought battle over case G 3/19. The decision upheld Article 53(b) EPC: “European patents shall not be granted in respect of plant or animal varieties or essentially biological processes for the production of plants or animals; this provision shall not apply to microbiological processes or the products thereof.”

This bitterly-fought connected car battle between Nokia and Daimler has seen almost all procedural tricks that one could imagine in patent disputes. This includes anti-anti-suit-injunctions across the Atlantic, involvement of the EU Commission and the German Federal Cartel Office, and a full injunction win for Nokia weakened by a seven billion euro security deposit. Daimler and its suppliers challenged this, with a request to stay the enforcement of the injunction.